Persistent molecular remission of refractory acute myeloid leukemia with inv(16)(p13.1q22) in an elderly patient induced by cytarabine ocfosfate hydrate by Masahisa Arahata et al.
JOURNAL OF HEMATOLOGY
& ONCOLOGY
Arahata et al. Journal of Hematology & Oncology  (2015) 8:5 
DOI 10.1186/s13045-014-0100-6LETTER TO THE EDITOR Open AccessPersistent molecular remission of refractory acute
myeloid leukemia with inv(16)(p13.1q22) in an
elderly patient induced by cytarabine ocfosfate
hydrate
Masahisa Arahata1*, Yukihiro Shimizu1, Hidesaku Asakura2 and Shinji Nakao3Abstract
The prognosis of relapsed acute myeloid leukemia (AML) in elderly patients is dismal, even if the AML exhibits a
good prognostic karyotype, such as inv(16)(p13.1q22). We present a 72-year-old female with AML with inv(16)
(p13.1q22) who suffered five episodes of relapse with temporary complete remission. Maintenance chemotherapy
with oral cytarabine ocfosfate hydrate eventually produced persistent molecular complete remission of her AML
that had not been induced by conventional regimens including intensive chemotherapy and low dose cytarabine
therapy. The high level of tolerability to oral cytarabine ocfosfate hydrate may offer elderly patients with this type of
AML a good chance for a cure.
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Acute myeloid leukemia (AML) with inv(16)(p13.1q22)
is characterized by a favorable prognosis and good re-
sponse to treatment with cytarabine [1]. The strategy of
treatment for AML with inv(16)(p13.1q22) is based on a
series of intensive chemotherapy, which is considered
more curable than prolonged maintenance chemother-
apy with low-dose anti-leukemic agents even in the
elderly [2-4]. On the other hand, low-dose cytarabine
therapy (LDAC) is recommended for elderly patients
with AML who are not considered suitable for intensive
chemotherapy [5-8], but LDAC can rarely induce per-
sistent remission [9]. Once they relapse, their prognosis
is usually dismal, even if the AML is associated with inv
(16)(p13.1q22) [10,11].
Case presentation
In December 2006, a 72-year-old female was admitted to
our hospital presenting with general malaise and dys-
pnea. A physical examination revealed anemic palpebral* Correspondence: rqxhf297@yahoo.co.jp
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unless otherwise stated.conjunctiva and purpura of the extremities. The com-
plete blood count indicated severe anemia and throm-
bocytopenia as well as mild leukocytosis with 22.5% blast
cells (Additional file 1). A bone marrow examination
showed a total nucleated cell count of 41,000/μL with
67.0% blasts (Additional file 2: Figure S1A). A cytogenetic
analysis of the bone marrow cells with G-banding showed
46,XX,inv(16)(p13.1q22) in all 20 dividing cells (Additional
file 2: Figure S1B). Based on these findings, the patient
was diagnosed as having AML with inv(16)(p13.1q22).
The patient achieved complete remission (CR) after
one course of induction chemotherapy comprising behe-
noyl cytarabine and daunorubicin according to a study
protocol [12] (Table 1). However, the AML relapsed four
months after the completion of the last cycle of consoli-
dation therapy. Re-induction chemotherapy using the
same regimen as the first induction induced a second
CR. Thereafter, the patient suffered four further episodes
of relapse with temporary remission (Figure 1). The fail-
ure to achieve durable remission even with high-dose
consolidation therapy and its toxicities prompted us to
select palliative care with LDAC at the third relapse.
After achieving the sixth CR, the patient declined further
treatment with LDAC due to toxicity. Therefore, orall. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Table 1 Chemotherapy regimens and adverse events in the present case
Chemotherapy No. Regimen PS BI
Grade of adverse event*
BW(kg) Complications
Neutropenia FN orinfecton Anemia Thrombocytopenia Anorexia
Weight
loss
Onset to 1st CR Induction 1 BHAC 200 mg/m2 IV day 1-8 3 100 4 3 4 4 3 1 44.4
DNR 40 mg/m2 IV day 1-3
Consolidation 2 BHAC 200 mg/m2 IV day 1-5 2 100 4 3 4 4 3 1 41.6 Sepsis
MIT 7 mg/m2 IV day 1-3
3 BHAC 200 mg/m2 IV day 1-5 1 100 4 3 3 3 3 1 40.8
DNR 25 mg/m2 IV day 1-2
ETP 100 mg/m2 IV day 1-3
4 BHAC 200 mg/m2 IV day 1-5 1 100 4 3 2 2 2 1 40.5
ACR 10 mg/m2 IV day 1-5
1st relapse to
2nd CR
Induction 5 BHAC 200 mg/m2 IV day 1-8 4 55 4 3 4 3 3 2 39.0 Osteoporotic lumbar
compression fracture
Pulmonary AspergillosisDNR 40mg/m
2 IV day 1-3
Consolidation 6 BHAC 200 mg/m2 IV day 1-6 2 100 4 3 3 2 2 2 38.5
DNR 40 mg/m2 IV day 1-3
7 Ara-C 1 g/m2 IV x2 day 1-5 1 100 4 3 4 3 3 3 36.9
2nd relapse to
3rd CR
Induction 8 LDAC day 1-14 with M-CSF
day 15-28
3 100 4 3 3 4 3 3 36.5
9 LDAC day 1-14 with M-CSF
day 1-14
2 100 4 None 3 4 3 3 34.9
Consolidation 10 Same as # 9 1 100 3 None 3 3 3 3 35.2
11 Same as # 9 1 100 3 None 3 3 3 3 36.4
12 Same as # 9 1 100 3 None 4 3 3 3 36.4
13 Same as # 9 1 100 2 None 3 3 3 2 37.5
3rd relapse to
4th CR
Induction 14 LDAC day 1-14 with M-CSF
day 1-14
1 100 4 3 3 4 3 2 37.5
VPA 600 mg/day PO
15 LDAC day 1-12 with M-CSF
day 1-14
1 100 3 None 3 3 3
VPA 600 mg/day PO
Consolidation 16 Same as # 15 1 100 3 None 3 3 3 1 41.3
17 LDAC day 1-10 with M-CSF
day 1-14
1 100 3 3 2 3 3 2 39.1
















Table 1 Chemotherapy regimens and adverse events in the present case (Continued)
18 Same as # 17 1 100 3 3 2 3 3 2 39.4
19 Same as # 17 1 100 3 None 3 3 3 1 40.6
4th relapse to
5th CR
Induction 20 LDAC day 1-10 with M-CSF
day 1-14
3 95 4 3 4 4 3 1 42.4
21 SPAC 200 mg/day PO day 1-14 1 95 None None 3 None 2
G-CSF 100 μg SC day 1-14
22 Same as # 21 1 95 3 None 2 2 1 1 41.2
23 LDAC day 1-10 with M-CSF
day 1-14
2 100 4 3 4 4 3 1 42.0
24 LDAC day 1-12 with M-CSF
day 1-14
3 100 4 3 4 4 3 1 41.6
25 LDAC day 1-12 with G-CSF
day 1-12
3 100 4 3 4 4 3 1 42.2
ACR 14 mg/m2 IV day 1-4
26 Same as # 25 2 100 3 3 3 3 3 1 41.7
Consolidation 27 Same as # 25 1 100 3 None 3 3 2
28 Same as # 25 1 100 4 None 3 3 2 2 39.6
29 Same as # 25 1 100 4 None 3 4 2 2 39.5
30 Same as # 25 1 100 4 None 3 4 2
5th relapse to
6th CR
Induction 31 LDAC day 1-12 with G-CSF
day 1-12
3 5 4 3 4 4 3 1 40.8 Depression
ACR 14 mg/m2 IV day 1-4
32 MTX 15 mg + Ara-C 40mg + PSL
10mg IT day -1
4 5 4 3 4 4 4 Traumatic lumbar
compression fracture
LDAC day 1-10 with G-CSF
day 1-12
ACR 14 mg/m2 IV day 1-4
Consolidation 33 LDAC day 1-10 with G-CSF
day 1-12
3 5 4 3 3 3 3
ACR 14 mg/m2 IV day 1-4
34 Same as # 33 1 75 4 None 3 3 3 None 44.0
35 Same as # 33 1 90 4 None 3 4 3 None 44.6
Maintenance 36 SPAC 300 mg/day PO day 1-7 every
4-6 weeks
1 100 None None None None 2 2 36.0 Sarcopenia
ACR: aclarubicin hydrochloride, Ara-C: cytarabine, BHAC; behenoyl cytarabine, BI: Barthel index, BW: body weight, DNR: daunorubicin hydrochloride, ETP: etoposide, FN: febrile neutropenia, G-CSF: lenograstim 100 μg
subcutaneously injected or lenograstim 250 μg intravenously injected, IT: intrathecal injection, IV: intravenous injection, LDAC: cytarabine 10 mg/m2 subcutaneously injected twice a day, M-CSF: mirimostim 8 million
units intravenously injected, MIT: mitoxantrone hydrochloride, PO: per oral, PS: performance status, SC: subctaneous injection.
















Figure 1 Clinical course of the patient. FISH: fluorescence in situ hybridization, (+): positive, (−): negative. *The karyotype was obtained from
peripheral blood cells at that time because the patient rejected a bone marrow aspiration procedure.
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to maintain remission in November 2011. The SPAC
therapy was not associated with any significant tox-
icity. The CBFB-MYH11 fusion mRNA in the peripheral
blood became negative after twelve courses of SPAC ther-
apy, which was terminated in October 2013. The patient
has since remained in molecular remission without chemo-
therapy (Figure 1).Discussion
Our patient received lower doses of cytarabine and
daunorubicin than the doses that are considered as
standard doses for remission induction of AML with inv
(16)(p13.1q22) nowadays, and the suboptimal doses of
induction chemotherapy may be the cause of her early
relapse. However, higher doses of cytarabine and dauno-
rubicin may have put the 72-year-old woman’s life in
danger due to associated toxicities. The frail woman
eventually went into deep remission after maintenance
therapy with a cytarabine prodrug SPAC.
SPAC has been shown to be as effective and tolerable
as LDAC in treatment of AML [13-15], though its use-
fulness of SPAC is not well recognized because it is not
available outside Japan. In this case, the AML cells were
considered as highly sensitive to cytarabine because of
repetitive achievement of CR induced by LDAC. Besides,
SPAC was associated with fewer toxicities than LDAC
(Table 1). LDAC requires the use of subcutaneous injec-
tions twice a day, but elderly patients often have dif-
ficulties visiting the hospital frequently. On the otherhand, SPAC can be orally administered at home.
These advantages enabled our patient to continue the
maintenance therapy for two years and contributed
to her persistent molecular remission. Thus, SPAC
potentially offers a chance of cure for elderly patients
with inv(16)(p13.1q22) without life threatening
toxicities.Consent
Written informed consent was obtained from the patient
for publication of this case report and any accompanying
images. A copy of the written consent is available for re-
view by the Editor-in-Chief of this journal.Additional files
Additional file 1: Table S1. Laboratory data of the patient at diagnosis.
ALT: alanine aminotransferase, ALP: alkaline phosphatase, APTT: activated
partial thromboplastin time, AST: aspartate aminotransferase, AT-III:
antithrombin-III, CRP: C-reactive protein, γ-GTP: γ-glutamyltranspeptidase,
LDH: lactate dehydrogenase, PT-INR: international normalized ratio of the
prothrombin time, T-Bil: total bilirubin, T-Cho: total cholesterol.
Additional file 2: Figure S1. Smear and karyogram of bone marrow
aspirates. A: May-Giemsa-stained smear (x1,000). The blue arrows indicate
myeloblasts and monoblasts. The percentage of eosinophils was elevated
up to 16.0% of all nucleated cells. The immunophenotype of the blasts
was CD2+, CD13+, CD33+, CD34+ and HLA-DR+ (data is not shown). B:
Karyogram determined by G-banding. The red arrow indicates inv(16)
(p13.1;q22).Abbreviations
AML: Acute myeloid leukemia; CR: Complete remission; LDAC: Low-dose
cytarabine therapy; SPAC: Cytarabine ocfosfate hydrate.
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